Ken Griffin Brainstorm Cell Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.22 - $0.42 $1,562 - $2,982	-7,100 Reduced 17.75%	32,900 $7,000
Q2 2024 Aug 14, 2024	SELL	$0.34 - $0.74 $3,536 - $7,696	-10,400 Reduced 20.63%	40,000 $13,000
Q1 2024 May 15, 2024	SELL	$0.28 - $0.66 $6,608 - $15,576	-23,600 Reduced 31.89%	50,400 $28,000
Q4 2023 Feb 14, 2024	SELL	$0.15 - $0.4 $8,250 - $22,000	-55,000 Reduced 42.64%	74,000 $19,000
Q3 2023 Nov 14, 2023	BUY	$0.2 - $2.08 $18,080 - $188,032	90,400 Added 234.2%	129,000 $25,000
Q2 2023 Aug 14, 2023	SELL	$2.0 - $3.2 $53,800 - $86,080	-26,900 Reduced 41.07%	38,600 $79,000
Q1 2023 May 15, 2023	SELL	$1.43 - $3.3 $91,091 - $210,210	-63,700 Reduced 49.3%	65,500 $216,000
Q4 2022 Feb 14, 2023	BUY	$1.37 - $4.42 $25,482 - $82,212	18,600 Added 16.82%	129,200 $211,000
Q3 2022 Nov 14, 2022	BUY	$2.55 - $4.42 $41,565 - $72,046	16,300 Added 17.29%	110,600 $489,000

10.8M

160K

30.5K

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $63.5M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.